Synapse - Don't let the HCT-CI fool you: Similar outcomes with myeloablative CD34+ selected allo-HCT compared to unmodified RIC allo-HCT in patients with AML or MDS and high comorbidity scores

Don't let the HCT-CI fool you: Similar outcomes with myeloablative CD34+ selected allo-HCT compared to unmodified RIC allo-HCT in patients with AML or MDS and high comorbidity scores Meeting Abstract

Authors:	Pennisi, M.; Cho, C.; Devlin, S. M.; Ruiz, J. D.; Maloy, M. A.; Tomas, A. A.; Castillo, N.; Lin, R. J.; Politikos, I.; Sanchez-Escamilla, M.; Scordo, M.; Shah, G. L.; Barker, J. N.; Castro-Malaspina, H.; Gyurkocza, B.; Dahi, P. B.; Jakubowski, A. A.; Papadopoulos, E. B.; Ponce, D. M.; Sauter, C. S.; Shaffer, B. C.; Shouval, R.; Tamari, R.; van den Brink, M. R. M.; Young, J. W.; Giralt, S. A.; Perales, M.
Abstract Title:	Don't let the HCT-CI fool you: Similar outcomes with myeloablative CD34+ selected allo-HCT compared to unmodified RIC allo-HCT in patients with AML or MDS and high comorbidity scores
Meeting Title:	Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR
Journal Title:	Biology of Blood and Marrow Transplantation
Volume:	26
Issue:	3 Suppl.
Meeting Dates:	2020 Feb 19-23
Meeting Location:	Orlando, FL
ISSN:	1083-8791
Publisher:	Elsevier Inc.
Date Published:	2020-03-01
Start Page:	S152
End Page:	S153
Language:	English
ACCESSION:	WOS:000516887900220
PROVIDER:	wos
DOI:	10.1016/j.bbmt.2019.12.704
Notes:	Meeting Abstract: 221 -- Source: Wos